Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

IGILUC 2019 /
Beyond second-line therapy: New hope for mCRC patients in Egypt

18th - 19th Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.05.19
Views: 663
Rating:

Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA

Prof Heinz-Josef Lenz speaks to ecancer at the 2019 International Gastrointestinal, Liver and Uro-Oncology Conference (IGILUC) in Cairo about the use of TAS-102 for the treatment of metastatic colorectal cancer (mCRC) in Egypt.

Prof Lenz discusses the data that support TAS-102 for the treatment of mCRC, along with its mechanism of action and side effects. He also compares the efficacy and toxicity profiles of both regorafenib and TAS-102.

For the future, Prof Lenz states that more targets still need to be identified - for example, genetic alterations or mutations.
 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation